Broadfin Capital, Celsus: Broadfin Capital, managed by Kevin Kotler, just disclosed a position in Celsus Therapeutics (OTCQB: CLSXY). According to a SEC filing, Broadfin purchased around 3.5 million shares of Celsus, which represents an 8.9% position in the company. At the current price of Celsus’s stock, the value of Broadfin’s position in the company amounts to over $14 million. Earlier today, Broadfin Capital also disclosed initiating a stake in another biopharmaceutical company, Idera Pharmaceuticals.
Celsus Therapeutics recently entered into a securities purchasing agreement, which will bring the company gross proceeds worth some $12.5 million. Under the agreement, Celsus sold around 22 million ordinary shares at a price of $0.57 apiece to a group of unnamed institutional healthcare investors. Celsus Therapeutics is a clinical stage company engaged in the development of a new type of anti-inflamatory drugs.
Recommended Reading:
Kevin Kotler’s Broadfin Capital Joins HealthCor in Idera
Phil Frohlich’s Prescott Group Is Buying More China Marine Food Stock
Columbia Wanger Asset Management Loves Boingo Wireless, Closes Out on This Trio
